Genmab — August 2019

[Vitus]

Klap lige hesten bibob...

[Bella1]

Husk at tage kopipapir med til indpakning, - næsten ingen holder fysisk avis mere, og fiskehandlerne klager deres nød

[Plimsoller]

Det er svært at finde malurten i bægeret i øjeblikket.

[bibob]

Vitus. Har ingen hest.

[bibob]

Bella1. Jeg har Børsen på tryk. Den kan ikke bruges til andet.

[E_L]

on Pleiades, data is still very young, As of the data cutoff (4 March 2019),

median duration of follow up was approximately 7
months for D-VMP and D-Rd and 4 months for DVRd

[E_L]

so by the end of the year that will be 14 and 11 months, i assume that is enough for a broad label SC approval?

[bibob]

Har dette Ph 4 Dara mono i MM været vist. ?? https://www.clinicaltrials.gov/ct2/show/NCT03768960?term=Darzalex&cond=Multiple+Myeloma&rank=2

[E_L]

i had seen it, but was a bit surprised it was a Ph 4

[E_L]

another Dara abstract - OAB-060
A Prospective Phase II of Daratumumab in
Previously Treated Systemic Light-Chain
(AL) Amyloidosis: Updated Results

[E_L]

CONCLUSIONS: Monotherapy with
DARA demonstrates encouraging efficacy in
previously treated pts with AL amyloidosis with
deep and rapid hematological responses with a good
safety profile. The Andromeda phase 3 study
comparing CyborD with or without DARA is
ongoing.

[Sukkeralf]

Lets hope Andromeda interim data read out in late 2019 will be positive

[Sukkeralf]

It could be rather cool if both ofatumumab in MS and daratumumab in Amyloidosis and teprotumumab in TED all get on the market - then its suddenly quit a bit more income in the coming years¨

[E_L]

and then a a CD3xCD20 deal to top it off early next year

[E_L]

FP-117
Preclinical evaluation of the new
GPRC5DxCD3 (JNJ-7564) bispecific
antibody for the treatment of multiple
myeloma

[E_L]

Conclusion: GPRC5D
is highly and selectively expressed on MM cells,
which makes it an attractive therapeutic target. The
GPRC5DxCD3 bispecific antibody, JNJ-7564,
effectively lysed MM cell lines and primary MM
cells in samples derived from both newly diagnosed
and heavily pretreated patients, including DARArefractory patients.

[Sukkeralf]

Nothing about the BCMA/CD3 antibody?

[E_L]

FP-149
Safety of rapid daratumumab infusion in
relapsed and refractory multiple myeloma

[E_L]

Daratumumab infusion
time of 90 minutes was well tolerated, thus allowing
a considerable saving of time for RRMM patients
and potentially ameliorating their adherence to
treatment

[E_L]

i am still searching for interesting Dara hits, there are 289 in that book, so bear with me